Discovery STREAM

  1. Saudi Arabia Government Leaders Discuss Agile Manufacturing Beyond Borders 10/23/2022

    Learn how government leaders in Saudi Arabia planned for biopharma resilience beyond borders and used agile manufacturing to prepare for the unknown.

  2. A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol 1/23/2025

    Learn about a novel LCMS assay for 4β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

  3. How To Best Optimize mRNA Production Workflows 4/11/2023

    Multiple steps in the mRNA manufacturing process can appear more complex than they have to be. Learn how to simplify your approach and produce the best possible mRNA vaccines and therapeutics.

  4. Meet Your Bioprocess Sidekick For Cell Culture Media Analysis 6/10/2022

    You need rapid and reliable nutrient profiles to make informed decisions, and waiting on that data has detrimental effects on your process. See how REBEL fills the gap.

  5. Pragmatic Computational Biology with Andrew Satz 9/20/2023

    This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?

  6. Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D. 10/20/2025

    In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.

  7. Don't Be A D**k With Ochre Bio's Dr. Quin Wills 9/27/2023

    Don't be offended by the title of today's Business of Biotech podcast. Dr. Quin Wills' application of what's become known as "Wheaton's Law" (look it up) is central to the ambitious goals his company, Ochre Bio, is pursuing: pioneering the value of computational biology in large mol discovery and development, putting an end to the global liver disease epidemic, and changing the costly, high-risk approach to clinical trials. On this week's episode, Dr. Wills and I explore how those goals are being addressed despite the challenges they present, and how the company's three guiding principles, don't be a d**k being one of them, align the Ochre team with the mission at hand. 

  8. Can You Run Crude Samples Using An SPR Instrument? 2/17/2022

    We explore a common misconception and provide examples of complex material being used in an SPR system.

  9. Inside A Dopamine-Restoring Cell Therapy For PD With BlueRock Therapeutics' Dr. Amit Rakhit 12/4/2024

    On this episode of Cell & Gene: The Podcast, Host Erin Harris, invites BlueRock Therapeutics' Dr. Amit Rakhit to take a deep dive into therapy options for Parkinson's disease (PD). They discuss how BlueRock's bemdaneprocel's mechanism of action differs from traditional PD treatments, the limitations of current PD medications, and much more.

  10. Streamline Your mRNA Purification Steps 3/4/2025

    Ensure your mRNA's stability and effectiveness post-transcription with advanced filtration and chromatography techniques to enhance purity and recovery, which delivers high-quality mRNA for superior therapeutics and vaccines.